, Volume 14, Issue 4, pp 651–659 | Cite as

IGF1 deficiency in newly diagnosed Graves’ disease patients

  • Sorina Martin
  • Anca Sirbu
  • Minodora Betivoiu
  • Suzana Florea
  • Carmen Barbu
  • Simona Fica
Research paper


OBJECTIVE: Thyroid hormones influence the GH/IGF1 axis, but previous studies have reported discrepant results regarding serum IGF1 levels in hyperthyroidism. We have therefore investigated, at diagnosis, the relationship between serum IGF1 levels and the main characteristics of Graves’ disease (GD): severity of hyperthyroidism, goiter size, presence of active Graves’ ophthalmopathy (GO), antythyroid antibodies status and titer. DESIGN AND METHODS: This cross-sectional study included 98 newly diagnosed hyperthyroid patients with GD who presented consecutively at our clinic. The main measured parameters were: TSH, FT4, FT3, TT3, thyroglobulin, anti-thyroid peroxidase antibodies (TPOAb), anti-thyroglobulin antibodies (ATA), thyrotropin receptor antibodies (TRAb), IGF1. Patients were considered IGF deficient if IGF1 z score was ≤-2SD from mean for age. RESULTS: In GD patients, men had higher IGF1 levels (p=0.023) and IGF1 z scores (p=0.013) than women. 18.4% of GD patients were, at diagnosis, IGF1 deficient. Compared to patients without IGF1 deficiency, these patients presented higher thyroglobulin (median=72.55, IQR=116.02 vs median=11.40, IQR=80.74 ng/ml, p=0.002) and FT3 (median=11.30, IQR=7.64 vs median=7.33, IQR=5.72 pg/ml, p=0.027), and lower ATA (median=20, IQR=0 vs median=34.05, IQR=161 iu/ml, p<0.001) levels. Thyroglobulin was independently associated with IGF1 deficiency (AUROC=0.732, 95% CI: 0.620–0.844, p=0.002; cut-off for thyroglobulin=50.40 ng/ml, Se=77.8%, Sp=70%). IGF1 status was not influenced by gender (p=0.084), current smoking (p=0.558), goiter size (p=0.533), active ophthalmopathy (p=0.334), TRAb (p=0.239) or TPOAb status (p=0.367). CONCLUSIONS: Nearly one fifth of newly diagnosed GD patients had IGF1 deficiency. IGF1 deficiency was associated with lower ATA titers, higher thyroglobulin levels and more severe FT3 hyperthyroidism at diagnosis.

Key words

Anti-thyroglobulin antibodies IGF1 IGF1 deficiency Graves’ disease Thyroglobulin 


  1. 1.
    Rapoport B, McLachlan SM, 2007 The thyroptin receptor in Graves’ disease. Thyroid 17: 911–922.CrossRefGoogle Scholar
  2. 2.
    Eckstein AK, Plicht M, Lax H, et al, 2006 Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91: 3464–3470.CrossRefGoogle Scholar
  3. 3.
    Gerding MN, Van der Meer JWC, Broenink M, et al, 2000 Association of thyrotrophin receptor antibodies with the clinical features of Graves’ ophthalmopathy. Clin Endocrinol 52: 267–271.CrossRefGoogle Scholar
  4. 4.
    Bartalena L, Fatourechi V, 2014 Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest 37: 691–700.CrossRefGoogle Scholar
  5. 5.
    Tramontano D, Cushing GW, Moses AC, Ingbar SH, 1986 Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves’-IgG. Endocrinology 119: 940–942.CrossRefGoogle Scholar
  6. 6.
    Wiersinga WM, 2011 Autoimmunity in Graves’ Ophthalmopathy: The Result of an Unfortunate Marriage Between TSH Receptors and IGF-1 Receptors. J Clin Endocrinol Metab 96: 2386–2394.CrossRefGoogle Scholar
  7. 7.
    Tsui S, Naik V, Hoa N, et al, 2008 Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease. J Immunol 181: 4397–405.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Frystyk J, Grønbaek H, Skjaerbaek C, Flyvbjerg A, 1995 Effect of hyperthyroidism on circulating levels of free and total IGF-I and IGFBPs in rats. Am J Physiol 269: 840–845.Google Scholar
  9. 9.
    Ramos-Dias JC, Yateman M, Camacho-Hübner C, Grossman A, Lengyel AM, 1995 Low circulating IGF-I levels in hyperthyroidism are associated with decreased GH response to GH-releasing hormone. J. Clinical Endocrinology 43: 583–589.CrossRefGoogle Scholar
  10. 10.
    Iglesias P, Bayon C, Mendez J, Gancedo PG, Grande C, Diez JJ, 2001 Serum insulin-like growth factor type 1, insulin-like growth factor-binding protein-1, and insulin-like growth factor-binding protein-3 concentrations in patients with thyroid dysfunction. Thyroid 11: 1043–1048.CrossRefGoogle Scholar
  11. 11.
    Co Ng LL, Lang CH, Bereket A, Purandare A, Smaldone A, Wilson TA, 2000 Effect of hyperthyroidism on insulin-like growth factor-I (IGF-I) and IGF-binding proteins in adolescent children. J. Pediatr Endocrinol Metab 13: 1073–1080.CrossRefGoogle Scholar
  12. 12.
    Valcavi R, Dieguer C, Zini M, Muruais C, Casanueva F, Portioli I, 1993 Influence of hyperthyroidism on growth hormone secretion, Influence of hyperthyroidism on growth hormone secretion. J Clinical Endocrinology 38: 515–522.CrossRefGoogle Scholar
  13. 13.
    Miell JP, Taylor AM, Zini M, Maheshwari HG, Ross RJ, Valcavi R, 1993 Effects of hypothyroidism and hyperthyroidism on insulin-like growth factors (IGFs) and growth hormone- and IGF-binding proteins. J Clin Endocrinol Metab 76: 950–955.PubMedGoogle Scholar
  14. 14.
    Lakatos P, Foldes J, Nagy Z, et al, 2000 Serum insulin-like growth factor-I, insulin-like growth factor binding proteins, and bone mineral content in hyperthyroidism. Thyroid 10: 417–423.CrossRefGoogle Scholar
  15. 15.
    Krassas GE, Pontikides N, Kaltsas T, et al, 2003 Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. J Clin Endocrinol Metab 88: 132–135.CrossRefGoogle Scholar
  16. 16.
    Werner SC, 1977 Modification of the classification of the eye changes of Graves’ disease: recommendations of the ad hoc committee of the American Thyroid Association. J Clin Endocrinol Metab 44: 203–209.CrossRefGoogle Scholar
  17. 17.
    Mourits MP, Prummel MF, Wiersinga WM, Koornneef L, 1977 Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxford) 47: 9–14.CrossRefGoogle Scholar
  18. 18.
    Elmlinger MW, Kuhnel W, Weber NM, Ranke MB, 2004 Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med 43: 654–664.Google Scholar
  19. 19.
    Glynn N, Agha A, 2012 Diagnosing growth hormone deficiency in adults. Int J Endocrinol 2012: 972617.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Inukai T, Takanashi K, Takebayashi K, Fujiwara Y, Tayama K, Takemura Y, 1999 Thyroid hormone modulates insulin-like growth factor-I(IGF-I) and IGF-binding protein-3, without mediation by growth hormone, in patients with autoimmune thyroid diseases. Horm Metab Res 31: 576–579.CrossRefGoogle Scholar
  21. 21.
    Cissewski K, Wolf M, Moses AC, 1992 Characterization of insulin-like growth factor receptors in human thyroid tissue, Receptor 2: 145–153.PubMedGoogle Scholar
  22. 22.
    Hsiao PJ, Tsai JH, 1994 Increased insulin-like growth factor-1 receptors in thyroid tissues of Graves’ disease. J Formos Med Assoc 93: 925–932.PubMedGoogle Scholar
  23. 23.
    Morovat A, Dauncey MJ, 1998 Effects of thyroid status on insulin-like growth factor-I, growth hormone and insulin are modified by food intake. Eur J Endocrinol 138: 95–103.CrossRefGoogle Scholar
  24. 24.
    Tada H, Watanabe Y, Futakuchi Y, Amino N, 1994 Change in serum concentration of insulin-like growth factor II (IGF-II) in patients with thyroid disease. Endocr J 41: 541–545.CrossRefGoogle Scholar
  25. 25.
    Wan Nazaimoon WM, Khalid BA, 1998 Insulin-like growth factor binding protein-3 (IGFBP-3) but not insulin-like growth factor-I (IGF-I) remains elevated in euthyroid TSH-suppressed Graves disease. Horm Metab Res 30: 213–216.CrossRefGoogle Scholar
  26. 26.
    Zimmermann-Belsing T, Juul A, Juul Holst J, Feldt-Rasmussen U, 2004 The insulin-like growth axis in patients with autoimmune thyrotoxicosis: effect of antithyroid drug treatment. Growth Horm IGF Res 14: 235–244.CrossRefGoogle Scholar
  27. 27.
    Rosario PW, 2010 Normal values of serum IGF-1 in adults: results from a Brazilian population. Arq Bras Endocrinol Metabol 54: 477–481.CrossRefGoogle Scholar
  28. 28.
    Colao A, Di Somma C, Cascella T, et al, 2008 Relationships between serum IGF 1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. Eur J Endocrinol 159: 389–397.CrossRefGoogle Scholar
  29. 29.
    Vestergaard PF, Hansen M, Frystyk J, et al, 2013 Serum levels of bioactive IGF1 and physiological markers of ageing in healthy adults. Eur J Endocrinol 170: 229–236.CrossRefGoogle Scholar
  30. 30.
    Kaklamani VG, Linos A, Kaklamani E, Markaki I, Mantzoros C, 1999 Age, sex, and smoking are predictors of circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3. J Clin Oncol 17: 813–817.CrossRefGoogle Scholar
  31. 31.
    Palmer RM, Wilson RF, Coward PY, Scott DA, 2002 Analysis of circulating insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) in tobacco smokers and non-smokers. Tob Induc Dis 1: 157–170.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Krassas GE, Pontikides N, Kaltsas T, et al, 2003 Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. J Clin Endocrinol Metab 88: 132–135.CrossRefGoogle Scholar
  33. 33.
    Perrild H, Hansen JM, Arnung K, Olsen PZ, Danielsen U, 1986 Intellectual impairment after hyperthyroidism. Acta Endocrinol (Copenh) 112: 185–191.CrossRefGoogle Scholar
  34. 34.
    Kirkegaard C, Faber J, 1998 The role of thyroid hormones in depression. Eur J Endocrinol 138: 1–9.CrossRefGoogle Scholar
  35. 35.
    Lonn L, Stenlof K, Ottosson M, Lindroos AK, Nystrom E, Sjostrom L, 1998 Body weight and body composition changes after treatment of hyperthyroidism. J Clin Endocrinol Metab 83: 4269–4273.PubMedGoogle Scholar
  36. 36.
    Muller MJ, Seitz HJ, 1984 Thyroid hormone action on intermediary metabolism. Part III. Protein metabolism in hyper- and hypothyroidism. Klin Wochenschr 62: 97–102.CrossRefGoogle Scholar
  37. 37.
    Puche JE, Castilla-Cortázar I, 2012 Human conditions of insulin-like growth factor-I (IGF-I) deficiency. J Transi Med 10: 224.CrossRefGoogle Scholar
  38. 38.
    Clemmons DR, 2006 Clinical utility of measurements of insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2: 436–446.CrossRefGoogle Scholar
  39. 39.
    O’Connor JC, McCusker RH, Strie K, Johnson RW, Dantzer R, Kelley KW, 2008 Regulation of IGF-I function by proinflammatory cytokines: at the interface of immunology and endocrinology. Cell Immunol 252: 91–110.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2015

Authors and Affiliations

  • Sorina Martin
    • 1
    • 2
  • Anca Sirbu
    • 1
    • 2
    • 3
  • Minodora Betivoiu
    • 2
  • Suzana Florea
    • 4
  • Carmen Barbu
    • 1
    • 2
  • Simona Fica
    • 1
    • 2
  1. 1.Endocrinology DepartmentCarol Davila University of Medicine and Pharmacy Elias HospitalBucharestRomania
  2. 2.Endocrinology DepartmentElias HospitalBucharestRomania
  3. 3.Victor Babes InstituteElias HospitalBucharestRomania
  4. 4.Laboratory DepartmentElias HospitalBucharestRomania

Personalised recommendations